Engene Therapeutics Inc (ENGN) - News Archive

enGene Holdings Inc. Hits Significant Milestones with Q3 2025 Financials and Strategic AdvancesIn a notable stride towards therapeutic innovation, enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage, non-viral gene th...

Breakthrough in Bladder Cancer Treatment: enGene Achieves Key Milestone in Phase 2 LEGEND Trial enGene Holdings Inc. Reaches Target Enrollment in Pivotal Cohort for High-Risk NMIBC Trial BOSTON & MONTREAL enGene Holding...

enGene Holdings Inc.: Strategic Leadership Appointments and Financial Progress in Non-Viral Gene-Based Immunotherapy enGene Holdings Inc., a Boston and Montreal-based clinical-stage company specializing in non-viral gen...

In a recent announcement under NASDAQ Listing Rule 5635(c)(4), Engene Holdings Inc has disclosed a strategic management of its liabilities, leading to notable advancements in its financial health for the first quarter o...

enGene Reports Full Year 2024 Financial Results and Business Update Amid Promising Developments in Cancer Therapy BOSTON & MONTREAL enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company known f...

A Pivotal Period for enGeneBOSTON & MONTREAL enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company, has recently unveiled its financial results for the third quarter of 2024, alongside a signif...

An Update from the Realm of Genetic Medicine: enGene Reports Third Quarter Financials Amidst a Pivotal Clinical Journey In the year of our Lord, two thousand and twenty-four, enGene Holdings Inc. a distinguished enterpr...

Boston & Montreal-based enGene Holdings Inc. (Nasdaq: ENGN), a genetic medicines company specializing in non-viral, intravesical treatments, has released its financial results for the second quarter ended April 30, 2024...